Study shows certain gastrointestinal tumors associated with higher mortality
(University of California - San Diego) Researchers at University of California, San Diego School of Medicine have determined that certain gastrointestinal stromal tumors are more deadly than previously reported in medical literature. Findings are published online in the Journal of Gastrointestinal Surgery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 5, 2016 Category: Cancer & Oncology Source Type: news

Detecting BRAF V600E-Mutated Gastrointestinal Stromal TumorsDetecting BRAF V600E-Mutated Gastrointestinal Stromal Tumors
The authors evaluated the utility of a BRAF V600E mutant-specific monoclonal antibody in the detection of BRAF-mutated GISTs. American Journal of Clinical Pathology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 24, 2015 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

Laparoscopic Surgery for Gastrointestinal Stromal TumorsLaparoscopic Surgery for Gastrointestinal Stromal Tumors
This study compares postoperative outcomes and oncologic results of laparoscopic versus open surgery for gastric gastrointestinal stromal tumors. Annals of Surgery (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 16, 2015 Category: Intensive Care Tags: General Surgery Journal Article Source Type: news

GIST Recurrence Risk Underestimated 'in a Third of Patients'GIST Recurrence Risk Underestimated 'in a Third of Patients'
Many patients with resected gastrointestinal stromal tumors (GIST) are missing out on recommended adjuvant therapy. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 10, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study: With GIST Patients, Be Vigilant for Other CancersStudy: With GIST Patients, Be Vigilant for Other Cancers
In this first population-based study to look at the link between gastrointestinal stromal tumors and other cancers, researchers found patients with GIST have an increased risk for other malignancies. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 7, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Esophageal Gastrointestinal Stromal Tumor EnucleationEsophageal Gastrointestinal Stromal Tumor Enucleation
How feasibile is surgical enucleation of esophageal gastrointestinal stromal tumors? Annals of Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 27, 2015 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news

New at-risk group identified for gastrointestinal stromal tumors
(University of California - San Diego) Researchers at the University of California, San Diego School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors, which occur primarily in the lining of the stomach and small intestine. One key finding: Patients of Asian descent, who have not previously been identified as an at-risk population, are 1.5 times more likely than other patient groups to be diagnosed with this type of tumor. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 7, 2014 Category: Global & Universal Source Type: news

Bayer's Stivarga endorsed for gastrointestinal stromal tumors
FRANKFURT (Reuters) - German drugmaker Bayer said its Stivarga cancer drug was recommended for approval for the treatment of gastrointestinal stromal tumors by an expert panel at the European Union's healthcare regulator. (Source: Reuters: Health)
Source: Reuters: Health - June 27, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Newspath June 2013 - Gastrointestinal Stromal Tumors
Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors almost exclusively occurring along the GI tract. (Source: NewsPath - Pathology News for the Medical Community)
Source: NewsPath - Pathology News for the Medical Community - June 4, 2013 Category: Pathology Source Type: news

Tool Could Help Discover New Compounds, Combinations; Quickly Identify Most Effective Gastrointestinal Stromal Tumor Treatments
A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors (GISTs), providing a boost to animal research and possibly patient care, according to new findings presented by Fox Chase Cancer Center at the AACR Annual Meeting 2013... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2013 Category: Consumer Health News Tags: GastroIntestinal / Gastroenterology Source Type: news

Stivarga Approved By FDA For Advanced Gastrointestinal Stromal Tumors (GIST)
Stivarga (regorafenib), a cancer medication, has had its usage expanded to include patients suffering from advanced gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration. The drug is marketed by Bayer HealthCare Pharmaceuticals. GIST occurs when cancerous cells build up inside the gastrointestinal tract. There are between 3,000 to 6,000 new cases of GIST every year in the U.S, according to data published by the National Cancer Institute. As a multi-kinase inhibitor, Stivarga prevents cancer growth by blocking the key enzymes that make the cancer spread... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 26, 2013 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news

Horizon scanning: US FDA approves regorafenib for advanced gastrointestinal stromal tumors
Source: US FDA Area: News The U.S. Food and Drug Administration (FDA) has approved regorafenib (Stivarga) for the treatment of patients with advanced gastrointestinal stromal tumours (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease - imatinib and sunitinib.   The approval is based on the results of the GRID trial, previously reported on the NeLM in November 2012 - please see link below details. (Source: NeLM - News)
Source: NeLM - News - February 26, 2013 Category: Drugs & Pharmacology Source Type: news

FDA approves cancer drug Stivarga for advanced gastrointestinal stromal tumors
The US Food and Drug Administration today announced it has expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be removed and do not respond to other forms of approved… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 26, 2013 Category: Pharmaceuticals Source Type: news

FDA Approves Stivarga for Advanced Gastrointestinal Stromal Tumors
February 25, 2013 -- The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 25, 2013 Category: Drugs & Pharmacology Source Type: news

Bayer’s Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Gastrointestinal Stromal Tumors (for specialized target groups only)
Stivarga shown in a pivotal Phase III trial to significantly improve progression-free survival in patients with gastrointestinal stromal tumors (GIST) whose disease had progressed after previous treatments (Source: Bayer Company News)
Source: Bayer Company News - February 25, 2013 Category: Pharmaceuticals Source Type: news